Dr. Reddy’s receives EIR from USFDA

Dr Reddy's Laboratories Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA)

96
USFDA Inspection audit
USFDA Inspection

Last Updated on January 24, 2024 by The Health Master

Dr. Reddy’s receives EIR from USFDA

Dr Reddy’s Laboratories Ltd has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA) for Srikakulam formulations plant unit I, indicating closure of the audit.

The inspection classification of this facility is determined as “No Action Indicated” (NAI). Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Also read” EU GMP Certification for Biocon

The company’s therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news